Liposomes &
Nanosomes
Characterization Services
Advanced Physicochemical Characterization of Liposomal & Nanoparticulate Drug Delivery Systems.
Comprehensive analytical characterization services for liposomes, lipid nanoparticles (LNPs), nanosomes, polymeric nanoparticles, nanoemulsions, micelles, and complex nanomedicines using orthogonal analytical techniques aligned with USFDA, EMA, ICH, and global regulatory expectations.
Specialized Expertise for Nanomedicine Characterization
Accuprec Research Labs Pvt. Ltd. provides advanced characterization services for liposomal formulations, nanosomes, lipid nanoparticles, and complex nanomedicines. Our scientific team supports pharmaceutical companies, nanotechnology developers, CDMOs, and research organizations with comprehensive analytical solutions for product development, comparability assessment, regulatory submissions, and lifecycle management.
Nanoparticulate drug delivery systems possess highly complex structural and physicochemical properties that require extensive orthogonal analytical characterization to ensure:
- Product quality
- Stability
- Drug encapsulation efficiency
- Safety
- Therapeutic performance
- Regulatory compliance
What Are Liposomes & Nanosomes?
Liposomes and nanosomes are nanoscale carrier systems designed to improve:
- Drug solubility
- Controlled release
- Targeted delivery
- Bioavailability
- Therapeutic efficacy
- Stability of sensitive molecules
These systems typically consist of:
- Lipid bilayer vesicles
- Nanoparticle colloidal dispersions
- Encapsulated APIs
- Surface-modified nanocarriers
- Complex particle populations
Nanomedicine Platforms We Support
| Technology | Application |
|---|---|
| Liposomes | Injectable & topical drug delivery |
| Lipid Nanoparticles (LNPs) | mRNA & nucleic acid delivery |
| Polymeric Nanoparticles | Controlled drug release |
| Nanoemulsions | Solubility enhancement |
| Nanosomes | Advanced nano-delivery systems |
| Micelles | Poorly soluble drug delivery |
| Solid Lipid Nanoparticles (SLNs) | Sustained release applications |
Why Characterization Is Critical
Nanomedicines Are Highly Sensitive to:
- Manufacturing process changes
- Particle size variation
- Surface chemistry modifications
- Encapsulation efficiency
- Colloidal stability
- Storage conditions
Regulatory Agencies Require Comprehensive Characterization to Establish:
- Product consistency
- Batch reproducibility
- Structural similarity
- Quality attributes
- Clinical performance comparability
Extensive Characterization Is Essential for:
- Generic nanomedicine development
- Liposomal product equivalence
- Product optimization
- Stability studies
- Regulatory submissions
- Lifecycle management
Our Characterization Capabilities
Particle Size Distribution Analysis
Evaluation of:
- Z-average diameter
- D10 / D50 / D90 distribution
- Polydispersity Index (PDI)
- Nanoparticle aggregation behavior
Zeta Potential Analysis
Assessment of:
- Surface charge
- Colloidal stability
- Dispersion behavior
Encapsulation Efficiency & Drug Loading
Quantification of:
- Encapsulated drug
- Free drug
- Drug loading efficiency
- Entrapment efficiency
Morphological Characterization
Nanostructure evaluation using:
- TEM
- SEM
- Cryo-TEM
- AFM
Lipid & Excipient Characterization
Comprehensive profiling of:
- Phospholipids
- Cholesterol
- Surfactants
- Stabilizers
- Polymer systems
In-Vitro Drug Release Studies
Controlled release profile evaluation under simulated physiological conditions.
Stability Assessment
Characterization under:
- Accelerated conditions
- Long-term stability
- Freeze-thaw cycles
- Stress conditions
Advanced Analytical Technologies
Dynamic Light Scattering (DLS)
Particle size and colloidal distribution analysis.
Nanoparticle Tracking Analysis (NTA)
Particle concentration and size distribution characterization.
Transmission Electron Microscopy (TEM)
Visualization of nanoparticle morphology and vesicle structure.
Cryo-TEM
Advanced imaging of native liposomal structures in their hydrated state.
HPLC / UPLC / LC-MS/MS
Quantitative assay and impurity profiling of encapsulated and free drug.
Differential Scanning Calorimetry (DSC)
Thermal characterization of lipid bilayer systems.
FTIR & Raman Spectroscopy
Chemical and structural characterization of nanoparticle systems.
ICP-MS
Trace elemental impurity analysis.
Comparative Characterization Studies
Accuprec supports comprehensive analytical comparability studies for:
- Generic liposomal products
- Complex injectable nanomedicines
- Reference listed drug (RLD) comparison
- Product development optimization
Comparative Evaluation Includes:
- Particle size distribution
- Surface charge characteristics
- Encapsulation efficiency
- Drug release profiles
- Morphological similarity
- Stability comparison
Products & Dosage Forms We Support
We support characterization of:
Liposomal injections
Liposomal topical formulations
Lipid nanoparticle systems
mRNA delivery systems
Polymeric nanoparticles
Nanoemulsions
Micellar formulations
Ophthalmic nanoparticles
Injectable nanomedicines
Transdermal nanoformulations
Regulatory Support
Accuprec Supports:
- ANDA submissions
- Complex generic development
- Nanomedicine characterization packages
- Product development programs
- Regulatory deficiency response support
Studies Are Designed Considering:
USFDA Liposome GuidanceProduct-specific expectations for liposomal and nanoparticulate generics
EMA Nanomedicine ExpectationsEuropean regulatory framework for complex nanomedicines
ICH Q8/Q9/Q10 PrinciplesQuality by design and lifecycle management requirements
Scientific Comparability ApproachesEvidence-based comparability aligned with current regulatory science
Scientific Precision for Complex Nanomedicines
Advanced Nanotechnology Infrastructure
- State-of-the-art nanoparticle characterization facility
- Advanced orthogonal analytical instrumentation
- Dedicated nanomedicine analytical laboratories
Experienced Scientific Team — Expertise in:
- Liposomal formulations
- Nanotechnology characterization
- Colloidal systems
- Injectable nanomedicines
- Complex generic development
Comprehensive Orthogonal Approach
Multiple analytical techniques for complete physicochemical and structural profiling of complex liposomal and nanoparticulate systems.
Regulatory-Focused Documentation
Detailed scientific reports suitable for ANDA, complex generic, and global regulatory submissions.
End-to-End Nanomedicine Support
From early-stage product development through comparability assessment and lifecycle management.
Our Nanoparticle Characterization Process
Product & Formulation Assessment
Understanding formulation composition and analytical objectives.
Characterization Strategy Design
Selection of suitable orthogonal analytical techniques tailored to the nanoparticle system.
Method Development & Optimization
Optimization of analytical procedures for nanoparticle systems.
Comprehensive Characterization
Execution of physicochemical, structural, and comparative studies.
Statistical Evaluation & Reporting
Scientific interpretation with regulator-ready documentation.
Requirement Understanding
We define a clear analytical strategy aligned to your formulation and regulatory objectives.
Orthogonal Platform Selection
DLS, NTA, Cryo-TEM, DSC, HPLC and spectroscopic platforms selected for complete profiling.
Testing & Analysis
Physicochemical, structural, encapsulation, release and stability characterization.
Reporting & Regulatory Support
Audit-ready reports supporting ANDA, complex generic, and global regulatory filings.
Industries We Support
Pharmaceutical manufacturers
Nanomedicine developers
CDMOs
Biopharmaceutical companies
Research organizations
Advanced drug delivery developers
Injectable formulation manufacturers
